Skip to main content

Table 3 Phenotypic resistance of isolated microorganisms (efficacy population)

From: Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

Microorganism

Resistance status

Streptococcus pneumoniae

Penicillin-R*

Penicillin-I*

Penicillin-S*

Not available

n = 217 (100%)

27/217 (12.4%)

2/217 (2.3%)

69/217 (31.8%)

116/217 (53.5%)

Haemophilus influenzae

β-lactamase pos.

---

β-lactamase neg.

Not available

n = 90 (100%)

6/90 (6.7%)

 

20/90 (22.2%)

64/90 (71.3%)

Moraxella catarrhalis

β-lactamase pos.

---

β-lactamase neg.

Not available

n = 19 (100%)

2/19 (10.5%)

 

3/19 (15.8%)

15/19 (73.7%)

Staphylococcus aureus

MRSA

---

MSSA

Not available

n = 62 (100%)

2/62 (3.2%)

17/62 (21.4%)

41/62 (66.1%)

Oxacillin-R

 

Oxacillin-S

 

0/62 (0%)

2/62 (3.2%)

 

Enterobacteriaceae spp.

ESBL producer

---

Non-ESBL producer

Not available

n = 211 (100%)

2/111 (1.8%)

11/111 (9.9%)

98/111 (88.3%)

  1. *R, I, S = resistant, intermediate resistant, sensitive, respectively. ESBL, extended-spectrum β-lactamase; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.